Comments
Sun Pharmaceutical informed the BSE on Thursday that its subsidiary Sun Pharma Laboratories has raised Rs 1,000 crore through non-convertible debentures.
"Sun Pharma Laboratories Limited, a wholly-owned subsidiary of the company, has raised, on Private Placement Basis, rupees one thousand crore only by allotment of 10,000 (ICRA) AAA/stable outlook rated unsecured redeemable non-convertible debentures of a face value of Rs. 10,00,000," Sun Pharma said in a BSE filing.
It said the debentures will be listed on BSE under two series with Series 1 debentures comprising 5,000 debentures amounting to rupees five hundred crore with a tenor of 24 months, and Series 2 debentures comprising 5,000 debentures amounting to rupees five hundred crores with a tenor of 39 months.
Sun Pharma stock was trading at Rs 794.10 on BSE, up 0.47 per cent at 12.30 pm.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.